Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

1.

Three-year clinical outcome in the Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III) trial: a randomised comparison between sirolimus-eluting stent implantation and zotarolimus-eluting stent implantation for the treatment of total coronary occlusions.

Teeuwen K, Van den Branden BJ, Koolen JJ, van der Schaaf RJ, Henriques JP, Tijssen JG, Kelder JC, Vermeersch PH, Rensing BJ, Suttorp MJ.

EuroIntervention. 2015 Mar 22;10(11):1272-5. doi: 10.4244/EIJY14M08_07.

2.

Long-term comparison of sirolimus-eluting and bare-metal stents in ST-segment elevation myocardial infarction.

Wijnbergen I, Tijssen J, Brueren G, Peels K, van Dantzig JM, Veer MV, Koolen JJ, Michels R, Pijls NH.

Coron Artery Dis. 2014 Aug;25(5):378-83. doi: 10.1097/MCA.0000000000000118.

PMID:
24736301
3.

Heart disease in the Netherlands: a quantitative update.

Leening MJ, Siregar S, Vaartjes I, Bots ML, Versteegh MI, van Geuns RJ, Koolen JJ, Deckers JW.

Neth Heart J. 2014 Jan;22(1):3-10. doi: 10.1007/s12471-013-0504-x. Erratum in: Neth Heart J. 2014 Mar;22(3):131-2. doi: 10.1007/s12471-014-0532-1.

4.

Improving the efficiency of the cardiac catheterization laboratories through understanding the stochastic behavior of the scheduled procedures.

Stepaniak PS, Soliman Hamad MA, Dekker LR, Koolen JJ.

Cardiol J. 2014;21(4):343-9. doi: 10.5603/CJ.a2013.0112. Epub 2013 Aug 30.

PMID:
23990186
5.

Multislice computed tomography angiography for noninvasive assessment of the 18-month performance of a novel radiolucent bioresorbable vascular scaffolding device: the ABSORB trial (a clinical evaluation of the bioabsorbable everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).

Nieman K, Serruys PW, Onuma Y, van Geuns RJ, Garcia-Garcia HM, de Bruyne B, Thuesen L, Smits PC, Koolen JJ, McClean D, Chevalier B, Meredith I, Ormiston J.

J Am Coll Cardiol. 2013 Nov 5;62(19):1813-4. doi: 10.1016/j.jacc.2013.07.030. Epub 2013 Aug 7. No abstract available.

6.

Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III): a randomised comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions.

Van den Branden BJ, Teeuwen K, Koolen JJ, van der Schaaf RJ, Henriques JP, Tijssen JG, Kelder JC, Vermeersch PH, Rensing BJ, Suttorp MJ.

EuroIntervention. 2013 Nov;9(7):841-53. doi: 10.4244/EIJV9I7A138.

7.

A randomized multicenter comparison of hybrid sirolimus-eluting stents with bioresorbable polymer versus everolimus-eluting stents with durable polymer in total coronary occlusion: rationale and design of the Primary Stenting of Occluded Native Coronary Arteries IV study.

Teeuwen K, Adriaenssens T, Van den Branden BJ, Henriques JP, Van der Schaaf RJ, Koolen JJ, Vermeersch PH, Bosschaert MA, Tijssen JG, Suttorp MJ.

Trials. 2012 Dec 15;13:240. doi: 10.1186/1745-6215-13-240.

8.

A brief mindfulness based intervention for increase in emotional well-being and quality of life in percutaneous coronary intervention (PCI) patients: the MindfulHeart randomized controlled trial.

Nyklíček I, Dijksman SC, Lenders PJ, Fonteijn WA, Koolen JJ.

J Behav Med. 2014 Feb;37(1):135-44. doi: 10.1007/s10865-012-9475-4. Epub 2012 Nov 23.

PMID:
23180285
9.

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators.

N Engl J Med. 2012 Nov 29;367(22):2089-99. doi: 10.1056/NEJMoa1206797. Epub 2012 Nov 5.

10.

Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.

Wijnbergen I, Helmes H, Tijssen J, Brueren G, Peels K, van Dantzig JM, Van' t Veer M, Koolen JJ, Pijls NH, Michels R.

JACC Cardiovasc Interv. 2012 Mar;5(3):313-22. doi: 10.1016/j.jcin.2011.11.009.

11.

Vascular tissue reaction to acute malapposition in human coronary arteries: sequential assessment with optical coherence tomography.

Gutiérrez-Chico JL, Wykrzykowska J, Nüesch E, van Geuns RJ, Koch KT, Koolen JJ, di Mario C, Windecker S, van Es GA, Gobbens P, Jüni P, Regar E, Serruys PW.

Circ Cardiovasc Interv. 2012 Feb 1;5(1):20-9, S1-8. doi: 10.1161/CIRCINTERVENTIONS.111.965301. Epub 2012 Feb 7.

12.

Assessment of optimum stent deployment by stent boost imaging: comparison with intravascular ultrasound.

Tanaka N, Pijls NH, Koolen JJ, Botman KJ, Michels HR, Brueren BR, Peels K, Shindo N, Yamashita J, Yamashina A.

Heart Vessels. 2013 Jan;28(1):1-6. doi: 10.1007/s00380-011-0202-9. Epub 2011 Oct 29.

PMID:
22038109
13.

Paclitaxel-coated balloon in combination with bare metal stent for treatment of de novo coronary lesions: an optical coherence tomography first-in-human randomised trial, balloon first vs. stent first.

Gutiérrez-Chico JL, van Geuns RJ, Koch KT, Koolen JJ, Duckers H, Regar E, Serruys PW.

EuroIntervention. 2011 Oct 30;7(6):711-22. doi: 10.4244/EIJV7I6A114.

14.

1-year outcome of TRIAS HR (TRI-stent adjudication study-high risk of restenosis) a multicenter, randomized trial comparing genous endothelial progenitor cell capturing stents with drug-eluting stents.

Klomp M, Beijk MA, Varma C, Koolen JJ, Teiger E, Richardt G, Bea F, van Geloven N, Verouden NJ, Chan YK, Woudstra P, Damman P, Tijssen JG, de Winter RJ.

JACC Cardiovasc Interv. 2011 Aug;4(8):896-904. doi: 10.1016/j.jcin.2011.05.011.

15.

The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions.

Grube E, Chevalier B, Smits P, Džavík V, Patel TM, Mullasari AS, Wöhrle J, Stuteville M, Dorange C, Kaul U; SPIRIT V Investigators.

JACC Cardiovasc Interv. 2011 Feb;4(2):168-75. doi: 10.1016/j.jcin.2010.11.006.

16.
17.

Rationale and design of EXPLORE: a randomized, prospective, multicenter trial investigating the impact of recanalization of a chronic total occlusion on left ventricular function in patients after primary percutaneous coronary intervention for acute ST-elevation myocardial infarction.

van der Schaaf RJ, Claessen BE, Hoebers LP, Verouden NJ, Koolen JJ, Suttorp MJ, Barbato E, Bax M, Strauss BH, Olivecrona GK, Tuseth V, Glogar D, Råmunddal T, Tijssen JG, Piek JJ, Henriques JP; EXPLORE investigators.

Trials. 2010 Sep 21;11:89. doi: 10.1186/1745-6215-11-89.

18.

Acute and subacute stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: incidence, predictors and clinical outcome.

Heestermans AA, van Werkum JW, Zwart B, van der Heyden JA, Kelder JC, Breet NJ, van't Hof AW, Dambrink JH, Koolen JJ, Brueren BR, Zijlstra F, ten Berg JM.

J Thromb Haemost. 2010 Nov;8(11):2385-93. doi: 10.1111/j.1538-7836.2010.04046.x.

PMID:
20831622
19.

Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry.

van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ, Koolen JJ, Brueren BR, Dambrink JH, Hautvast RW, Verheugt FW, ten Berg JM.

J Am Coll Cardiol. 2009 Apr 21;53(16):1399-409. doi: 10.1016/j.jacc.2008.12.055.

20.

Early versus delayed, provisional eptifibatide in acute coronary syndromes.

Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van 't Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK; EARLY ACS Investigators.

N Engl J Med. 2009 May 21;360(21):2176-90. doi: 10.1056/NEJMoa0901316. Epub 2009 Mar 30.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk